Search research articles
Contact Us
Filters
Showing results (21-30 of 62) with videos related to
Page
of 7
Sort By:
Cancer
|
July 27, 2012
Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T-cell non-Hodgkin lymphoma: Southwest Oncology Group Study S0350
Daruka Mahadevan, Joseph M Unger, Catherine M Spier, et al.
Cancer Research
|
July 19, 2005
Differential regulation of noxa in normal melanocytes and melanoma cells by proteasome inhibition: therapeutic implications
Yolanda Fernández, Monique Verhaegen, Thomas P Miller, et al.
Leukemia Research
|
November 17, 2012
Alisertib (MLN8237) an investigational agent suppresses Aurora A and B activity, inhibits proliferation, promotes endo-reduplication and induces apoptosis in T-NHL cell lines supporting its importance in PTCL treatment
Wenqing Qi, Catherine Spier, Xiaobing Liu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 1, 2012
Aurora A inhibitor (MLN8237) plus vincristine plus rituximab is synthetic lethal and a potential curative therapy in aggressive B-cell non-Hodgkin lymphoma
Daruka Mahadevan, Amy Stejskal, Laurence S Cooke, et al.
Biochemical Pharmacology
|
February 5, 2011
Aurora inhibitor MLN8237 in combination with docetaxel enhances apoptosis and anti-tumor activity in mantle cell lymphoma
Wenqing Qi, Laurence S Cooke, Xiaobing Liu, et al.
Plos One
|
June 4, 2014
Alisertib added to rituximab and vincristine is synthetic lethal and potentially curative in mice with aggressive DLBCL co-overexpressing MYC and BCL2
Daruka Mahadevan, Carla Morales, Laurence S Cooke, et al.
Blood
|
June 27, 2012
A phase 2 trial of standard-dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab plus bevacizumab for patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: SWOG 0515
Alison T Stopeck, Joseph M Unger, Lisa M Rimsza, et al.
Blood
|
August 6, 2005
A redox signature score identifies diffuse large B-cell lymphoma patients with a poor prognosis
Margaret E Tome, David B F Johnson, Lisa M Rimsza, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 24, 2012
Effectiveness of first-line management strategies for stage I follicular lymphoma: analysis of the National LymphoCare Study
Jonathan W Friedberg, Michelle Byrtek, Brian K Link, et al.
Leukemia & Lymphoma
|
April 18, 2009
A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest oncology group study S0108
Alison T Stopeck, Joseph M Unger, Lisa M Rimsza, et al.
Page
of 7
Search research articles
Search
Showing results (21-30 of 62) with videos related to
Sort By:
Page
of 7
Cancer
|
July 27, 2012
Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T-cell non-Hodgkin lymphoma: Southwest Oncology Group Study S0350
Daruka Mahadevan, Joseph M Unger, Catherine M Spier, et al.
Cancer Research
|
July 19, 2005
Differential regulation of noxa in normal melanocytes and melanoma cells by proteasome inhibition: therapeutic implications
Yolanda Fernández, Monique Verhaegen, Thomas P Miller, et al.
Leukemia Research
|
November 17, 2012
Alisertib (MLN8237) an investigational agent suppresses Aurora A and B activity, inhibits proliferation, promotes endo-reduplication and induces apoptosis in T-NHL cell lines supporting its importance in PTCL treatment
Wenqing Qi, Catherine Spier, Xiaobing Liu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 1, 2012
Aurora A inhibitor (MLN8237) plus vincristine plus rituximab is synthetic lethal and a potential curative therapy in aggressive B-cell non-Hodgkin lymphoma
Daruka Mahadevan, Amy Stejskal, Laurence S Cooke, et al.
Biochemical Pharmacology
|
February 5, 2011
Aurora inhibitor MLN8237 in combination with docetaxel enhances apoptosis and anti-tumor activity in mantle cell lymphoma
Wenqing Qi, Laurence S Cooke, Xiaobing Liu, et al.
Plos One
|
June 4, 2014
Alisertib added to rituximab and vincristine is synthetic lethal and potentially curative in mice with aggressive DLBCL co-overexpressing MYC and BCL2
Daruka Mahadevan, Carla Morales, Laurence S Cooke, et al.
Blood
|
June 27, 2012
A phase 2 trial of standard-dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab plus bevacizumab for patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: SWOG 0515
Alison T Stopeck, Joseph M Unger, Lisa M Rimsza, et al.
Blood
|
August 6, 2005
A redox signature score identifies diffuse large B-cell lymphoma patients with a poor prognosis
Margaret E Tome, David B F Johnson, Lisa M Rimsza, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 24, 2012
Effectiveness of first-line management strategies for stage I follicular lymphoma: analysis of the National LymphoCare Study
Jonathan W Friedberg, Michelle Byrtek, Brian K Link, et al.
Leukemia & Lymphoma
|
April 18, 2009
A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest oncology group study S0108
Alison T Stopeck, Joseph M Unger, Lisa M Rimsza, et al.
Page
of 7